Last updated: 11/03/2018 10:32:12
Follow-up study to evaluate the safety and immunogenicity of a HPV vaccine (580299) in North America
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Safety and immunogenicity study of an additional dose of HPV vaccine (580299) in young, adult women in North America.
Trial description: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This study will further evaluate induction of immune memory and anamnestic responses in women who previously took part in the primary study (580299/001) and follow-up study (580299/007). Subjects were aged 15-25 yrs at the time of entry into the primary study and participation in the follow-up study lasted approximately 6 years. In the primary and follow-up studies, subjects were protected against HPV-16 and HPV-18 endpoints and had sustained antibody responses to both vaccine types over at least 5.5 years of follow-up. All subjects from North American study sites that completed the follow-up study will be invited to take part in the current study. The study will evaluate the safety and immunogenicity of a dose of GSK Biologicals HPV vaccine (580299) in women who had been immunologically primed in the primary study.The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Number of subjects with anti-human papilloma virus-16 (anti-HPV-16) and anti-HPV-18 antibody titers greater than or equal to pre-defined cut-off values
Timeframe: At Day 7 and Month 1 (Day 30)
Anti-HPV-16 and anti-HPV-18 antibody titers
Timeframe: At Day 7 and at Month 1 (Day 30)
Secondary outcomes:
Number of subjects with anti-HPV-16 and anti-HPV-18 greater than or equal to pre-defined cut-off values
Timeframe: At Month 7 and Month 18
Anti-HPV-16 and Anti-HPV-18 Antibody Titers
Timeframe: At Month 7 and Month 18
Number of Subjects With Antibody Titers against other oncogenic HPV types (HPV-31 & HPV-45) greater than or equal to 59 EL.U/mL
Timeframe: Day 0, Month 1 (Day 30), Month 7 and Month 18
Anti-HPV-31 and anti-HPV-45 antibody titers
Timeframe: Day 7, Month 1 (Day 30), Month 7 and Month 18
Number of subjects with cluster of differentiation 4 (CD4) T cell-mediated immune responses specific to defined oncogenic HPV types
Timeframe: Day 0, Month 1 [Day 30], Month 7 and Month 18
Number of subjects with cluster of differentiation 8 (CD8) T cell-mediated immune responses specific to defined oncogenic HPV types
Timeframe: Day 0, Month 1 [Day 30], Month 7 and Month 18
Number of subjects with B cell-mediated immune responses specific to defined oncogenic HPV types
Timeframe: Day 0, Month 1 [Day 30], Month 7 and Month 18
Number of subjects seropositive for anti-HPV-16 and anti-HPV-18 antibodies in cervico-vaginal secretion samples
Timeframe: Day 0, Month 1 (Day 30), Month 7 and Month 18
Titers of anti-human Papilloma virus 16 (anti-HPV-16) and anti-human Papilloma virus 18 (anti-HPV-18) antibodies in Cervico-vaginal Secretion Samples
Timeframe: Day 0, Month 1 (Day 30), Month 7 and Month 18
Number of subjects reporting solicited local symptoms
Timeframe: Within 7 days after vaccination
Number of subjects reporting solicited general symptoms
Timeframe: Within 7 days of vaccination
Number of subjects reporting unsolicited adverse events (AE)
Timeframe: Within 30 days of vaccination
Outcome of any reported pregnancies
Timeframe: From Day 0 up to Month 18
Number of subjects with new onset of chronic diseases (NOCDs), new onset of autoimmune diseases (NOADs) and medically significant conditions (MSCs)
Timeframe: From Day 0 up to Month 18
Number of subjects reporting serious adverse events (SAEs)
Timeframe: From Day 0 up to Month 18
Interventions:
Enrollment:
116
Primary completion date:
2008-22-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Moscicki A-B et al. (2012) Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 31(1):234-241. doi: 10.1016/j.vaccine.2012.09.037.
Moscicki B et al. Anamnestic response elicited by a fourth dose of the HPV-16/18 ASO4-adjuvanted vaccine in young women. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2010 (EUROGIN). Monte Carlo, Monaco, 17-20 February 2010.
Moscicki B et al. Anamnestic response to non-vaccine types elicited by a fourth dose of the HPV-16/18 ASO4-adjuvanted vaccine in young women. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2010 (EUROGIN). Monte Carlo, Monaco, 17-20 February 2010.
Medical condition
Infections, Papillomavirus
Product
SB580299
Collaborators
Not applicable
Study date(s)
January 2008 to December 2009
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
15 - 25 years
Accepts healthy volunteers
Yes
- A subject whom the investigator believes that she can and will comply with the requirements of the protocol
- Must have received three doses of study vaccine or placebo control in study 580299/001.
- Pregnant or breastfeeding.
- A woman planning to become pregnant or planning to discontinue contraceptive precautions during the study until approximately 2 months after the last vaccination.
Inclusion and exclusion criteria
Inclusion criteria:
- A subject whom the investigator believes that she can and will comply with the requirements of the protocol
- Must have received three doses of study vaccine or placebo control in study 580299/001.
- Must have completed study 580299/007.
- Written informed consent must be obtained from the subject prior to enrollment in the study.
- Healthy subjects, as established by medical history and history-directed clinical examination before entering into the study.
- Subject must have a negative urine pregnancy test.
- Subject must be at least three months post-termination of a pregnancy.
- Subject must be of non-childbearing potential,or subjects are required to be abstinent or use adequate contraceptive precautions for 30 days prior to vaccination. Subjects are also required to agree to continue such precautions for two months after completion of the vaccination series.
Exclusion criteria:
- Pregnant or breastfeeding.
- A woman planning to become pregnant or planning to discontinue contraceptive precautions during the study until approximately 2 months after the last vaccination.
- Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned administration during the study period.
- Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of each dose of vaccine. Administration of some routine vaccines up to 8 days before each dose of study vaccine is allowed.
- Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period.
- previous administration of components of the investigational vaccine outside of protocol 580299/001.
- Any medically diagnosed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
- History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines,
- Hypersensitivity to latex
- Acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- Cancer or autoimmune disease under treatment.
- Administration of immunoglobulins and/or any blood products within the three months (90 days) preceding enrollment or planned administration during the study period.
- Acute disease at the time of enrollment. All vaccines can be administered to persons with a minor illness
- Heavy bleeding or heavy vaginal discharge in which a pelvic exam cannot be performed.
Trial location(s)
Location
GSK Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84109
Status
Study Complete
Location
GSK Investigational Site
Bardstown, Kentucky, United States, 40004
Status
Study Complete
Location
GSK Investigational Site
Augusta, Georgia, United States, 30912-3500
Status
Study Complete
Showing 1 - 6 of 17 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2008-22-12
Actual study completion date
2009-01-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website